To the Editor:
MicroRNAs (miRNAs) 1 regulate cardiac growth and conduction and play an important role in cardiac diseases (1 ). Several miRNAs are differentially produced in cardiac hypertrophic tissue, compared with normal tissue, and may contribute to the development of cardiomyocyte hypertrophy (2, 3 ). Hypertrophic cardiomyopathy (HCM) is frequently familial and caused by mutations in sarcomeric genes. To our knowledge, no study has reported the miRNA production profile in HCM tissues with sarcomeric gene mutations. To better define the molecular changes in HCM, we defined the production of well-characterized miRNAs in left ventricular (LV) heart tissue from 5 patients who underwent a cardiac transplantation and a control heart tissue (human LV tissue, Ambion/Applied Biosystems), and we compared their production profiles. Two of the patients were familial HCM patients who were carriers of missense mutations in the MYH7 2 (myosin, heavy chain 7, cardiac muscle, beta) gene (Val822Met and Arg453Cys). Three patients were cases of sporadic LV hypertrophy secondary to heart valve disease.
The study was approved by the Ethical Committee of Hospital Universitario Central Asturias (HUCA), and all of the patients provided written informed consent. We isolated total RNA with TRIzol (Invitrogen) and used the TaqMan MicroRNA Reverse Transcription Kit, Megaplex RT Human Pool A primers, and TaqMan human MicroRNA TLDA plate A (all from Applied Biosystems) to determine the production profile of 377 human miRNAs in the healthy LV tissues and in a pool of the 2 tissues with MYH7 mutations. Each sample was analyzed in triplicate, and the mean threshold cycle (C T ) value for each miRNA was normalized by using mammalian U6 as the reference gene. A P value Ͻ0.05 with respect to the -fold difference in miRNA production (HCM pool vs healthy LV tissue) was considered statistically significant. The detailed experimental procedure is available upon request to the corresponding author.
Compared with the healthy LV tissue, the HCM tissue showed an overall downregulation of miRNAs. Although the 2 tissues were not significantly different with respect to most of the miRNAs, with a C T difference between the 2 tissues of Ͻ4 (data not shown), the 2 tissues were significantly different with respect to the production of 19 of the miRNAs (Table 1) . These miRNAs were individually assayed in triplicate in the LV control and the 5 pathologic tissues via real-time TaqMan miRNA assays (Applied Biosystems). Ten miRNAs were underproduced (miR-1, miR-133b, miR-191, miR-208b, miR-218, miR-30b, miR-374, miR-454, and miR-495) in the 5 pathologic tissues, and 2 miRNAs were overproduced (miR-590 -5p and miR-92a). miR-495 was the only miRNA that differentiated hearts with and without sarcomeric mutations. Compared with the healthy tissue, miR-495 was underproduced in the 2 samples with MYH7 mutations and overproduced in the 3 samples without sarcomeric mutations. This miRNA is deregulated in primary muscular disorders but not in cardiac diseases. miR-590 -5p and miR-92a were overproduced in all of the pathologic tissues. Neither of these 2 miRNAs had previously been reported as deregulated in cardiac hypertrophy and other heart diseases.
miR-1 and miR-133 were underproduced in the hypertrophic tissues and have previously been implicated in cardiac development. They are significantly downregulated in hearts from patients with idiopathic and ischemic cardiomyopathies (4, 5 ). miR-208a and miR-208b are encoded by introns in the MYH6 (myosin, heavy chain 6, cardiac muscle, alpha) and MYH7 genes, respectively. In mice, the reexpression of Myh7 {myosin, heavy polypeptide 7, cardiac muscle, beta [Mus musculus]} and the production of miR208b is a characteristic of cardiac hypertrophy in response to pressure overload. In agreement with a role for these miRNAs in the development of HCM, miR-208a was also overproduced in the 2 patients with MYH7 mutations. Interestingly, the -fold change in miR-208a in one of the HCM patients was the highest among all the miRNAs analyzed in our study (Table 1) . The downregulation of miR-208b was lower in the 3 patients with cardiac hypertrophy secondary to valve disease, suggesting that the changes in production of this miRNA could differ between hypertrophic hearts with and without sarcomeric gene mutations.
Compared with other studies of samples from patients with heart failure, we analyzed pathologic tissues with a recognized sarcomeric mutation that would be the primary cause of the hypertrophy in these patients. Changes in miRNA production might differ between hypertrophic hearts with sarcomeric mu-tations and hearts in which the disease was secondary to another condition causing the hypertrophy. The difference between these cases and those without sarcomeric mutations should be replicated with other patients, including cases with mutations in different sarcomeric genes. We also studied failing explanted hearts that represented advanced stages of the disease; thus, we cannot exclude the possibility that some of the deregulated miRNAs were not representative of the changes at the initial stages of the disease. 
Long-Term Stability of Clinical Laboratory Data-Sodium as Benchmark
To the Editor:
For adequate longitudinal investigation of individual patients, clinicians rely on long-term stability of laboratory data. This requirement is also essential to maximize the benefits and outcome of clinical trials and epidemiologic studies extended over several years. The long-term stability of laboratory measurements has scarcely been documented, however, and quality criteria are lacking. We selected sodium measurement in serum/ plasma to serve as a benchmark for achievable stability, because this analyte receives the most attention by the in vitro diagnostics industry in terms of restricting lot-to-lot variation. Moreover, we believe that with these data as a benchmark, industry can establish specifications for the realistic stability of assays used for the measurement of other analytes. For this purpose, we investigated the sodium results from Ghent University Hospital (in serum and in lithium heparin-treated plasma) and Brussels University Hospital (in lithium heparintreated plasma) covering the period from December 2001 to August 2010 and from January 1997 to October 2010, respectively. We calculated the daily 10th, 50th, and 90th percentiles, with exclusion of the measurements made on weekends and holidays. The number of results per weekday for Ghent and Brussels gradually increased from 495 to 640 and from 279 to 420, respectively. Moving means (n ϭ 5) were calculated to visualize shifts of Ͼ1 mmol/L. For all data, we calculated the percentages of results Ͻ135 mmol/L, a cutoff typically used as an indicator for hyponatremia (1 ).
The Ghent laboratory measured sodium with an indirect ionselective electrode (ISE) method on a Modular P Analytics and Hitachi 917 analyzer, which was replaced in November 2006 by a Cobas 6000 c501 analyzer (all Roche Diagnostics). In the Brussels laboratory, the Vitros 950IRC was gradually replaced by 3 Vitros Fusion 5,1 FS analyzers (Ortho Clinical Diagnostics). Fig. 1 shows the 5-day moving means of the 50th percentile for the sodium results from the Ghent and Brussels laboratories. The longterm mean was 140.0 mmol/L (CV, 0.9%) for Ghent and 140.5 mmol/L (CV, 0.6%) for Brussels. Inspection of the 50th percentile documented 7 shifts for the Ghent laboratory and 10 for the Brussels laboratory. For Ghent, major shifts coincided with annual changes in ISE compensator lots. Reassign- 
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